ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCAX vs LXRX // EV/EBITDA & P/E VALUATION

Bicara Therapeutics Inc. (NASDAQ) VS. Lexicon Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: BCAX 0 — LXRX 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCAX VS. LXRX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCAX LXRX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -31.50% -3.50 LXRX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -16.64% -10.30% -6.34 LXRX /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 LXRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 17.5 29.1 -11.56 LXRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $643.9M $658.5M -$14.7M LXRX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCAX REV LXRX REV BCAX GROSS % LXRX GROSS % BCAX FCF LXRX FCF
FY 2025 $0 $49.8M — 98.0% -$107.1M -$67.9M
FY 2024 $0 $6.0M — 89.7% -$74.8M -$179.8M
FY 2023 $0 $1.1M — — -$45.6M -$161.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCAX // BETA —
LXRX // BETA —